Dr. Marc S. Hoffmann, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Perelman School of Med at the University of Pennsylvania (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 626
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: Perelman School of Med at the University of Pennsylvania
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
KS license 0438229 · MO license 2015019920
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Kansas Hospital Kansas City, KS
- University of Kansas Health System Olathe Hospital Olathe, KS
- University of Kansas Health System - St Francis Campus Topeka, KS
- Miami County Medical Center Paola, KS
Medical groups
- Select Physical Therapy Holdings Inc (2,024 clinicians)
- University of Kansas Hospital Authority (250 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 626
- Services billed
- 2,242
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 539 | 322 |
| Established patient office or other outpatient visit, 40-54 minutes | 297 | 162 |
| Established patient office or other outpatient visit, 20-29 minutes | 124 | 118 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 96 | 39 |
| New patient office or other outpatient visit, 60-74 minutes | 76 | 76 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 65 | 40 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 44 | 43 |
| Hospital discharge day management, 30 minutes or less | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Overland PArk, KS | 201 |
| Brukinsa (zanubrutinib) | 115 |
| Pantoprazole Sodium Other prescribers in Overland PArk, KS | 86 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Overland PArk, KS | 61 |
| Jaypirca (pirtobrutinib) | 48 |
| Venclexta (venetoclax) | 47 |
| Prednisone Other prescribers in Overland PArk, KS | 40 |
| Gabapentin Other prescribers in Overland PArk, KS | 39 |
| Xarelto (rivaroxaban) Other prescribers in Overland PArk, KS | 32 |
| Doxycycline Hyclate Other prescribers in Overland PArk, KS | 30 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 38 payments worth $23,851 in total to this clinician.
| Beone Medicines USA, Inc. | $20,473 |
|---|---|
| Novartis Pharmaceuticals Corporation | $1,766 |
| AbbVie Inc. | $1,284 |
| Adc Therapeutics America, Inc. | $226 |
| Merck Sharp & Dohme LLC | $25.70 |
| AstraZeneca Pharmaceuticals LP | $24.83 |
| Celgene Corporation | $18.62 |
| Genentech USA, Inc. | $18.42 |
| Consulting Fee | $20,400 |
|---|---|
| Travel and Lodging | $2,633 |
| Food and Beverage | $792 |
| Education | $25.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Beone Medicines USA, Inc. Jun 12, 2025 | Consulting Fee BRUKINSA · Oncology | $8,000 |
| Beone Medicines USA, Inc. Apr 1, 2025 | Consulting Fee | $4,800 |
| Beone Medicines USA, Inc. Apr 1, 2025 | Consulting Fee | $3,600 |
| Novartis Pharmaceuticals Corporation Jun 10, 2025 | Consulting Fee | $1,650 |
| Beone Medicines USA, Inc. Apr 1, 2025 | Consulting Fee | $1,200 |
| Beone Medicines USA, Inc. Apr 1, 2025 | Travel and Lodging travel to Leawood, KS | $785 |
| Beone Medicines USA, Inc. Jun 12, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Hopewell, NJ · in-kind | $742 |
| AbbVie Inc. Jan 20, 2025 | Consulting Fee IMBRUVICA · ONCOLOGY | $550 |
| Beone Medicines USA, Inc. Jun 12, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Hopewell, NJ · in-kind | $465 |
| Beone Medicines USA, Inc. Jun 12, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Hopewell, NJ · in-kind | $343 |
All 18 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Aug 22, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $300 |
| AbbVie Inc. Jul 14, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $300 |
| Beone Medicines USA, Inc. Jun 12, 2025 | Consulting Fee BRUKINSA · Oncology | $8,000 |
| Beone Medicines USA, Inc. Jun 12, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Hopewell, NJ · in-kind | $742 |
| Beone Medicines USA, Inc. Jun 12, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Hopewell, NJ · in-kind | $465 |
| Beone Medicines USA, Inc. Jun 12, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Hopewell, NJ · in-kind | $343 |
| Beone Medicines USA, Inc. Jun 12, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Hopewell, NJ | $56.00 |
| Beone Medicines USA, Inc. Jun 12, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Hopewell, NJ | $43.44 |
| Novartis Pharmaceuticals Corporation Jun 10, 2025 | Consulting Fee | $1,650 |
| Merck Sharp & Dohme LLC Apr 25, 2025 | Education ZERBAXA · INFECTIOUS DISEASE · in-kind | $25.70 |
| Beone Medicines USA, Inc. Apr 1, 2025 | Consulting Fee | $4,800 |
| Beone Medicines USA, Inc. Apr 1, 2025 | Consulting Fee | $3,600 |
| Beone Medicines USA, Inc. Apr 1, 2025 | Consulting Fee | $1,200 |
| Beone Medicines USA, Inc. Apr 1, 2025 | Travel and Lodging travel to Leawood, KS | $785 |
| Beone Medicines USA, Inc. Apr 1, 2025 | Travel and Lodging travel to Leawood, KS | $112 |
| Beone Medicines USA, Inc. Apr 1, 2025 | Travel and Lodging travel to Leawood, KS | $59.33 |
| Beone Medicines USA, Inc. Apr 1, 2025 | Travel and Lodging travel to Leawood, KS | $28.03 |
| AbbVie Inc. Jan 20, 2025 | Consulting Fee IMBRUVICA · ONCOLOGY | $550 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 17 industry-funded studies in 2025, from 9 companies. The companies reported $5,096,488 in research payments for these studies, mostly to the institutions running them.
- Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Beigene, Ltd. · Active, not recruiting · NCT06073821 - Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
Beone Medicines Ltd. · Active, not recruiting · NCT04277637 - A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Beone Medicines Ltd. · Recruiting · NCT06697184 - A phase 1b, open label, global, multicenter, dose determination, randomized dose expansion study to determine the maximum tolerated dose, assess the safety and tolerability, pharmacokinetics and preliminary efficacy o…
Celgene Corporation - A phase 1B2 openlabel study of PF07901801 in combination with glofitamab after a fixed single dose of obinutuzumab in participants with relapsedrefractory diffuse large b cell lymphoma not eligible for stem cell trans…
Pfizer Inc. - A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Anti-Lymphoma Agents in Subje…
E.r. Squibb & Sons, L.l.c. - A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously …
Celgene Corporation - A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma
Celgene Corporation - A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Beone Medicines Ltd. · Recruiting · NCT06634589 - A Phase I, Open-label, Multi-center Study of PIT565 in Patients With Relapsed and/or Refractory B-cell Malignancies
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.